You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Optimizing Asparaginase Therapy for Acute Lymphoblastic Leukemia: Oncology Pharmacist and Nurse Perspectives

  • Authors: Ryan J. Daley, PharmD, BCOP; Katherine L. Byar, MSN, ANP, BC, BMTCN
  • CE Released: 9/19/2022
  • Valid for credit through: 3/19/2023
Start Activity

Target Audience and Goal Statement

This activity is intended for oncology pharmacists, nurses, and nurse practitioners.

The goal of this activity is to provide oncology pharmacists and nurses with enhanced knowledge and competence on the use of asparaginase for the treatment of ALL including types of approved agents, efficacy, toxicity, and approaches for adverse event prevention and management, all of which will help to improve patient outcomes.

Upon completion of this activity, participants will:

  • Explain the rationale for use of asparaginase in the treatment of ALL
  • Recognize the differences among available forms of asparaginase
  • Describe the basis for selecting the best type of asparaginase based on patient-specific factors, and the optimal dose and route of administration
  • Formulate approaches for identifying and mitigating toxicities associated with asparaginase therapy to optimize treatment outcomes


Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Postgraduate Institute for Medicine (PIM), or Jazz Pharmaceuticals. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.


  • Ryan J. Daley, PharmD, BCOP

    Clinical Pharmacy Specialist, Leukemia
    Memorial Sloan Kettering Cancer Center
    New York, New York


    Disclosure: Ryan J. Daley, PharmD, BCOP, has the following financial relationships:
    Consultant or advisor for: Da Volterra (Paris, France)
    Ownership interest: (less than 5%) in Aprea Therapeutics, Inc.

  • Katherine L. Byar, MSN, ANP, BC, BMTCN

    Nurse Practitioner, Hematologic Malignancy
    Nebraska Medicine
    Fred & Pamela Buffett Cancer Center
    Omaha, Nebraska


    Disclosure: Katherine L. Byar, MSN, ANP, BC, BMTCN, has no relevant affiliations or financial relationships with a commercial interest.

The clinical reviewer, Lisa Holle, PharmD, BCOP, FHOPA, FISOPP, has no relevant affiliations or financial relationships with a commercial interest.

The writer, Thomas Cook, RPh, PhD, has no actual or potential conflicts of interest in relation to this program.  

Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

Accreditation Statements

Jointly Provided by Postgraduate Healthcare Education, LLC (PHE) and Postgraduate Institute for Medicine (PIM).

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Postgraduate Healthcare Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Designated for 0.75 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

    Published: August 26, 2022
    Expires: February 26, 2023

    Type of Activity: Application
    Media: Internet
    Fee Information: There is no fee for this educational activity.
    Estimated time to complete activity: 120 minutes

    If you have questions regarding the certification of this activity, please contact PIM via email at [email protected].


    Please ensure the computer system you plan to use meets the following minimum requirements:

    • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
    • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
    • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
    • Peripherals: Computer speakers or headphones
    • Monitor Screen Resolution: 320 x 480 or higher
    • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Optimizing Asparaginase Therapy for Acute Lymphoblastic Leukemia: Oncology Pharmacist and Nurse Perspectives

Authors: Ryan J. Daley, PharmD, BCOP; Katherine L. Byar, MSN, ANP, BC, BMTCNFaculty and Disclosures

CE Released: 9/19/2022

Valid for credit through: 3/19/2023


The slides from this presentation are considered intellectual property and for use as a professional resource.
No content should be copied or reproduced in any manner for any reason.

  • Print